BPC-157 is the recovery peptide this site is asked about most. Whether it helps a tendon heal is covered elsewhere on this site, and the short answer there is that nobody has run a controlled human trial. This page answers the question that matters first to anyone who is drug tested: what the rules say, whether a test can find it, and what has happened to the athletes who were caught. It gives no usage guidance, per our editorial standards.
What it is, in one paragraph
BPC-157 is a synthetic 15-amino-acid peptide, sequence GEPPPGKPADDAGLV, described as a fragment of a protein found in gastric juice. It is not approved as a medicine anywhere. The full "what is it" entry is Peptide Lexicon's BPC-157 page, its reported side effects are on Peptifact's BPC-157 side-effects page, and the healing evidence is counted on this site's pages on joints and tendons, recovery and the Wolverine stack, where it is usually paired with TB-500.
Status: named, at all times
WADA's 2026 Prohibited List, read on 2026-10-02, names BPC-157 in section S0, Non-Approved Substances. S0 prohibits at all times:
"Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use … This class covers many different substances including but not limited to BPC-157, 2,4-dinitrophenol (DNP), ryanodine receptor-1-calstabin complex stabilizers … and troponin activators."
Two consequences follow, both set out on WADA status by compound. It is prohibited in and out of competition, so a test taken in the off-season counts. And every S0 substance is a Specified Substance, which changes how much a sanction can be reduced when an athlete shows how it entered their system, not whether it is prohibited. BPC-157's usual partner TB-500 sits in a different section, S2, with different sanction rules.
The sanctions record
USADA publishes every sanction it announces in one table. Read on 2026-10-02, it held 1,075 entries. Three name BPC-157:
| Announced | Sport | Substances or reason, as published | Sanction |
|---|---|---|---|
| 2023-09-14 | Mixed martial arts | BPC-157 | 4-month suspension |
| 2024-08-22 | Speedskating | Non-analytical: use (BPC-157) | 1-year suspension |
| 2025-09-17 | Triathlon | BPC-157; TB-500; CJC-1295; ipamorelin | 4-year suspension; loss of results |
Three things stand out.
- The range is wide: four months to four years. The table does not give reasons, but the four-year case combined BPC-157 with three other prohibited peptides, two of them outside S0.
- One case had no positive test. "Non-analytical" means the violation was established by other evidence (an admission, records, a purchase), not a sample. Use counts, not just a positive.
- It is rare in the record, which says more about testing than about use. For scale, the same table names ostarine in 74 sanctions and GW1516 in 22. All three BPC-157 cases date from 2023 onwards, after laboratories had published methods for it (below).
This is USADA's record only: one national agency, published sanctions only. Other agencies and sports bodies keep their own.
Can a test find it?
Yes, and the methods have been public for years.
- 2017, Salt Lake City. The Sports Medicine Research and Testing Laboratory published a urine method after BPC-157 turned up in confiscated vials (Cox 2017, PMID 28035768). Limit of detection 0.1 ng/mL. BPC-157 forms a stable metabolite in plasma, which improves specificity, and was stable in urine for at least 4 days.
- 2023, Shanghai Anti-Doping Laboratory. Using carbon-13/nitrogen-15-labelled BPC-157, a doping-control group identified nine metabolites and validated a urine method for BPC-157 plus five of them at 0.01–0.11 ng/mL (Tian 2023, PMID 37959764).
- 2026, Ghent. A harmonised method detects 54 prohibited peptide and non-peptide substances, BPC-157 among them, in dried blood spots, serum and plasma. BPC-157 stayed detectable in dried spots for the whole storage study, though it degraded completely in serum left at 4–22 °C (Mazzarino 2026, PMID 42328738).
What none of these papers states is a detection window: how many days after a given amount a test would still find it. That needs controlled human dosing, and no such study was found. Any figure circulating online for how long BPC-157 "stays in the system" does not come from the anti-doping literature read here. The workplace versus anti-doping distinction, and why a standard employment panel does not look for peptides, is on peptides and drug testing.
The FDA question, and why it is not a sport question
On 23 July 2026 FDA's Pharmacy Compounding Advisory Committee discussed BPC-157 (free base and acetate) for the 503A bulks list, the list of substances pharmacies may compound from. FDA's meeting page, read 2026-10-02, lists the one use FDA reviewed for BPC-157: ulcerative colitis. TB-500 was reviewed for wound healing and MOTS-c for obesity and osteoporosis. No muscle, tendon or ligament use was on the table for any of them.
Two points for athletes. First, committee votes are advisory, and a bulks-list listing governs compounding; it is not an FDA approval of BPC-157 as a medicine. Second, S0's test is approval "for human therapeutic use" by a government health authority. Whether any future FDA action would move BPC-157 out of S0 is for WADA to decide, and the 2026 List names it. Peptifact's FDA category 2 page tracks the compounding lists themselves.
What the performance claim rests on
The claim behind BPC-157 in gyms is faster healing of tendons, ligaments and muscle. Those results come from rodents, and the few human reports are uncontrolled. The site's pages on joints and tendons and recovery count them one by one, and the Wolverine stack page reads the rat study that combined it with TB-500. No trial has measured performance, strength or return-to-play in athletes. For a tested athlete, the arithmetic is lopsided: a prohibited-at-all-times substance with published detection methods and a public sanctions record, against an unmeasured benefit.
The honest summary
- Named on WADA's 2026 List under S0; prohibited in and out of competition; Specified.
- 3 of 1,075 USADA published sanctions name it (2023, 2024, 2025): 4 months, 1 year, 4 years; one without a positive test.
- Urine methods to 0.1 ng/mL (2017) and 0.01–0.11 ng/mL with metabolites (2023); dried-blood-spot method in 2026. No published detection window.
- FDA's July 2026 compounding review covered ulcerative colitis only, and a compounding listing is not an approval.
- No athlete trial of any performance or recovery outcome.
Limits of this page
USADA's table lists sanctions as announced and summarises each in a few words; case decisions were not read for this page, and other agencies' records were not searched. The table's count was taken on one date and grows. Detection limits are laboratory performance figures, not windows in people. FDA's meeting page was read for the agenda and the uses reviewed; the committee's votes and any later FDA action are outside what this page reports.
Sources and dates
- World Anti-Doping Agency, 2026 Prohibited List, section S0 read 2026-10-02.
- U.S. Anti-Doping Agency, sanctions table, read 2026-10-02: 1,075 entries; rows naming BPC-157 (3), ostarine (74), GW1516 (22).
- Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal 2017;9:1490–8 — PMID 28035768
- Tian T, Jing J, Li Y, et al. Stable isotope labeling-based nontargeted strategy for characterization of the in vitro metabolic profile of a novel doping BPC-157 in doping control by UHPLC-HRMS. Molecules 2023;28:7345 — PMID 37959764
- Mazzarino M, Colpaert T, Deventer K, Van Eenoo P. Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. Analyst 2026;151:4398–413 — PMID 42328738
- U.S. Food and Drug Administration, July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee, agenda and "uses evaluated" chart read 2026-10-02.